Tyra Bioscience, Inc (TYRA)

Tyra Biosciences' stock has experienced significant fluctuations, with a 52-week range between $8.75 and $40.65, and a substantial six-month increase of 126.90%. Key events impacting the stock include the release of fourth quarter and full-year 2025 financial results on March 2, 2026, the appointment of Habib Dable to the Board of Directors on April 17, 2026, and participation in investor conferences announced on May 7, 2026. The company also reported its first quarter 2025 financial results on May 8, 2025.

There is no specific information available to indicate demand seasonality for Tyra Biosciences, Inc.'s products and services. Demand is primarily driven by disease prevalence, clinical trial progress, and the efficacy and safety profiles of its investigational therapies, rather than seasonal factors.

Tyra Biosciences, Inc. is a clinical-stage biotechnology company focused on developing next-generation precision medicines within the Health Technology sector. Their core focus is on targeted oncology and genetically defined conditions, utilizing their SNÅP platform for rapid and precise drug design. Key product candidates include Dabogratinib for urologic cancers and skeletal dysplasias, TYRA-430 for FGF19+/FGFR4-driven cancers, and TYRA-200 for metastatic intrahepatic cholangiocarcinoma.

Tyra Biosciences, Inc. is headquartered in Carlsbad, California, United States.

Tyra Biosciences generally holds a positive brand reputation among analysts. The company has received a consensus rating of "Moderate Buy" from analysts, with an average rating score of 2.92, based on 1 strong buy rating, 10 buy ratings, and 1 sell rating. Another analysis indicates a "Strong Buy" consensus from 9 analysts, with 56% recommending a Strong Buy and 44% recommending a Buy. Bulls highlight the potential of the SNAP platform and dabogratinib, while bears point to the limited product pipeline and concerns about efficacy and competition. Recent news and investor conference participation suggest positive engagement.

The ownership structure of Tyra Biosciences is a mix of institutional, retail, and individual investors. Approximately 13.29% of the company's stock is held by institutional investors, 29.54% by insiders, and 50.49% by public companies and individual investors. Major institutional owners include Ra Capital Management, L.p., Alta Partners Management Company, L.P., Commodore Capital Lp, Janus Henderson Group Plc, Vestal Point Capital, LP, Bvf Inc/il, BlackRock, Inc., Farallon Capital Management Llc, Vanguard Group Inc and Kynam Capital Management, LP. Peter Kolchinsky owns the most shares among individual investors.